MaxCyte to acquire Akron Bio for $151.8M; Q3 revenue up 49% to $10.2M

MAXCYTE, INC.

Deal: $105M cash + 20,639,733 MXCT shares (~$26.8M) + $20M deferred ($10M each in Jan 2028 and Jan 2029); total $151.8M.
Akron Bio expected 2026 revenue ~$28M and EBITDA $7-8M; products embedded in five approved therapies and >100 clinical programs.
Q3 2026 revenue $10.2M (+49% YoY): core $8.2M (+27%), SPL $2.0M vs $0.4M; gross margin 83%; net loss $4.8M vs $12.4M.
FY2026 revenue guidance raised to at least $34.5M (core ~$28M, SPL at least $6.5M); cash $132.7M at Sept 30.
MidCap facility up to $75M; expects $22M drawn at close. Deal needs HSR and Nasdaq listing approval, no stockholder vote; targeted before end-2026.

item 1.01 item 2.02 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.